Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
前收盤價
US$6.38
−US$0.21 · -3.19%
盤中時間採用ET。市場資料可能有所延遲。
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
日內區間
目前US$6.38
52週區間
目前US$6.38
盤中時間採用ET。市場資料可能有所延遲。
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
日內區間
目前US$6.38
52週區間
目前US$6.38
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1637.98萬 USD | 1016.72萬 USD | 719.9萬 USD | 668.1萬 USD | 687.3萬 USD |
| 銷貨成本 | 478.74萬 USD | 346.81萬 USD | 281.7萬 USD | 366萬 USD | 392.1萬 USD |
| 毛利 | 1159.24萬 USD | 669.91萬 USD | 438.2萬 USD | 302.1萬 USD | 295.2萬 USD |
| 研究與開發 | 2095.65萬 USD | 1615.04萬 USD | 1437.7萬 USD | 1469萬 USD | 1527.7萬 USD |
| 銷售、一般及管理費用 | 3261.21萬 USD | 2202.33萬 USD | 1862.1萬 USD | 1793.3萬 USD | 1796.6萬 USD |
| 營業費用 | 5356.86萬 USD | 3817.37萬 USD | 3299.8萬 USD | 3514.7萬 USD | 3324.3萬 USD |
| 利息收入 | 108.87萬 USD | 136.71萬 USD | 164.2萬 USD | 104.97萬 USD | 20.32萬 USD |
| 利息支出 | — | — | 77萬 USD | 16.71萬 USD | 6.64萬 USD |
| 折舊和攤銷 | 56.98萬 USD | 93.6萬 USD | 92.9萬 USD | 160.4萬 USD | 187.9萬 USD |
| 營業利益 | −4197.62萬 USD | −3147.46萬 USD | −2861.6萬 USD | −3212.6萬 USD | −3029.1萬 USD |
| 淨利 | −4331.52萬 USD | −2648.05萬 USD | −2856.9萬 USD | −2866.9萬 USD | −3069.9萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$11.00
上漲空間 72.41%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年10月16日 | 1:10 | — | — |
已生效 2019年10月16日
1:10
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。